

Welcome to the Surveillance **A**fter Extremity Tumor surger**Y** (SAFETY) Trial November Enrolment Update!


RECRUITMENT UPDATE

We are pleased to report that as of 1 November 2022, **173** participants have been enrolled in the SAFETY trial.

Congratulations to **Dr. Felasfa Wodajo** and the research team at **Virginia Cancer Specialists** in **Fairfax, VA, USA**, for opening to enrolment in the SAFETY trial!

| Site | Country | Enrolled Since Last Update | Enrolled to Date | Projected Yearly Enrolment | 2022 Enrolment |
|-----------------------------------------------|-----------|----------------------------|------------------|----------------------------|----------------|
| Juravinski Hospital and Cancer Centre | Canada | 0 | 54 | 15 | 17 |
| Hôpital Maisonneuve-Rosemont | Canada | 1 | 19 | 10 | 9 |
| Oregon Health and Science University | USA | 0 | 11 | 15 | 11 |
| Centro Traumatologico Ortopedico Hospital | Italy | 0 | 10 | 10 | 4 |
| Leiden University Medical Centre | NLD | 0 | 7 | 12 | 4 |
| Huntsman Cancer Institute | USA | 0 | 7 | 12 | 2 |
| Hospital de Clínicas de Porto Alegre | Brazil | 0 | 6 | 8 | 1 |
| L'Hôtel-Dieu de Quebec | Canada | 0 | 6 | 5 | 2 |
| Parkview Cancer Institute | USA | 0 | 6 | 10 | 6 |
| University of Florida Health Shands Hospital | USA | 0 | 6 | 10 | 0 |
| Medical University Graz | Austria | 0 | 5 | 8 | 1 |
| University of California Davis Medical Center | USA | 0 | 5 | 10 | 2 |
| McGill University Health Centre | Canada | 0 | 4 | 5 | 2 |
| Albany Medical Center | USA | 0 | 4 | 8 | 1 |
| Nova Scotia Health | Canada | 0 | 3 | 5 | 1 |
| The Ottawa Hospital | Canada | 1 | 4 | 5 | 4 |
| Cleveland Clinic | USA | 1 | 4 | 10 | 1 |
| Holden Comprehensive Cancer Centre | USA | 0 | 3 | 6 | 0 |
| NYU Langone Orthopaedic Hospital | USA | 0 | 3 | 5 | 0 |
| St. Vincent's Hospital Melbourne | Australia | 0 | 2 | 8 | 2 |
| Hartford HealthCare | USA | 0 | 2 | 6 | 2 |
| Montefiore Medical Centre | USA | 0 | 2 | 6 | 1 |
| Hospital Universitario Austral | Argentina | 0 | 0 | 8 | 0 |
| Mount Sinai Hospital | Canada | 0 | 0 | 12 | 0 |
| Texas Tech Health Sciences Center El Paso | USA | 0 | 0 | 10 | 0 |
| Virginia Cancer Specialists | USA | 0 | 0 | 10 | 0 |
| Total | | 3 | 173 | 229 | 73 |

2022 ENROLMENT GOAL



STUDY RESOURCES

You can find study resources at www.SAFETYrct.com by logging into the SAFETY Investigator section of our website:

Username: siteinvestigators

Password: SAFETYInvestigators1!

SAFETY UPDATES

VIRGINIA CANCER SPECIALISTS OPENS FOR ENROLMENT

Congratulations to Dr. Felasfa Wodajo and the research team at Virginia Cancer Specialists in Fairfax, VA, USA, for opening to enrolment! We appreciate the hard work of each enrolling site.



HELP US REACH 200 PARTICIPANTS

Congratulations to **Hôpital Maisonneuve-Rosemont, Oregon Health and Science University, and The Ottawa Hospital!** These sites are all on track to meet their yearly enrolment target for 2022.

We are 27 participants away from reaching our 2022 enrolment target of 200 participants. Please ensure all eligible participants are being approached for consent.

If you are unsure if a patient is eligible, reach out to the Methods Centre and we will be happy to answer your questions.

SAFETY PEARLS

POSITIVE MARGINS

Are patients with microscopically positive margins eligible to participate in the SAFETY trial?

Yes, please indicate that the margins were microscopically positive on the Baseline Tumor Pathology Report Form (Form 4.2).

Are patients with positive margins who undergo re-excision eligible to participate?

Yes, patients who undergo re-excision ND achieve negative or microscopically positive margins are eligible to participate. Please indicate the margins from the re-excision on the Baseline Tumor Pathology Report Form (Form 4.2).

CONSENT DEADLINE

Eligible patients can be approached for consent up to 90 days following completion of all active treatment.

UPLOADING SCREENING DATA TO iDATAFAX

To enter a Screening Form on iDataFax, you first need to add a new patient folder. This can be done by selecting **Patient > Start New Patient** and entering the applicable Patient ID. The Patient ID consists of your site number, plus the four-digit code indicating whether a participant was included, missed, or excluded. You can find more details in the [Study Resource Binder](#).

All screening data must be entered into iDataFax.

The **first** included patient at Site 01 will have a Participant ID of:

0 1 - 1 0 0 1

The **fifteenth** included patient at Site 10 will have a Participant ID of:

1 0 - 1 0 1 5

The **first** missed patient at Site 01 will have a Participant ID of:

0 1 - 2 0 0 1

The **tenth** missed patient at Site 10 will have a Participant ID of:

1 0 - 2 0 1 0

The **first** excluded patient at Site 01 will have a Participant ID of:

0 1 - 3 0 0 1

The **fifth** excluded patient at Site 10 will have a Participant ID of:

1 0 - 3 0 0 5

METHODS CENTRE CONTACTS

If you have questions about any aspect of the SAFETY trial, please contact us:

Dr. Michelle Ghert, Principal Investigator
ghertm@mcmaster.ca

Tricia Schneider*, Senior Project Manager
schnep@mcmaster.ca

Tess Hudson, Primary Project Manager
hudsontc@mcmaster.ca

Hadia Farrukh, Research Assistant
farrukhh@mcmaster.ca

* Tricia is currently on maternity leave. Please contact Tess with any study correspondence.